Overview

A Study of a New Type of Insulin in Participants With Type 2 Diabetes on Insulin Injection Therapy

Status:
Withdrawn
Trial end date:
2018-04-01
Target enrollment:
Participant gender:
Summary
The study will be conducted in participants with type 2 diabetes on insulin injection therapy to investigate how the body processes a test formulation of insulin lispro and the effect of the test formulation on blood sugar levels. Side effects and tolerability will be documented. The study will be conducted in two parts (Part A and Part B) to achieve its objectives. Participants are expected to enroll in both parts.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Insulin
Insulin Lispro
Insulin, Globin Zinc